Compare Freshworks Inc (FRSH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Freshworks Inc trades at $11.69 (market cap $3.31B), while Vertex Pharmaceuticals Incorporated trades at $529.34 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 40.6× Freshworks Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | VRTX | |
|---|---|---|
Market Cap | $3.31B | $134.25B |
Sector | Technology | Health |
52-Week High | $13.97 | $529.65 |
52-Week Low | $6.88 | $376.62 |
Enterprise Value | $2.68B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $11.98, up 1.18% with bullish technical signals and strong fundamentals. The company reported Q2 2026 revenue growth of 16% year-over-year, achieving its first GAAP profitability quarter with $3.2 million net income. Recent FedRAMP designation and Gartner leadership recognition highlight strategic progress. Analyst consensus shows 50% buy ratings with a $16.50 price target, suggesting 38% upside potential.
The outlook remains positive with accelerating revenue growth and improved profitability, though elevated P/E and EV/EBITDA ratios warrant caution. Key risks include competitive pressures in SaaS and execution challenges. Current momentum supports continued appreciation toward analyst targets, making FRSH attractive for growth-oriented investors despite valuation concerns.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
